医薬品安全性監視(ファーマコビジランス)の世界市場:臨床試験段階別(前臨床、第Ⅰ相、第Ⅱ相、第Ⅲ相、第Ⅳ相)、サービスプロバイダー別(インハウス、契約アウトソーシング)、種類別、エンドユーズ別

【英語タイトル】Pharmacovigilance Market Size, Share & Trends Analysis Report By Clinical Trial Phase (Pre-Clinical, Phase I, II, III, IV), By Service Provider (In-House, Contract Outsourcing), By Type, By End Use, And Segment Forecasts, 2019 - 2026

Grand View Researchが出版した調査資料(GV905091)・商品コード:GV905091
・発行会社(調査会社):Grand View Research
・発行日:2019年4月12日
・ページ数:170
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:Healthcare IT
◆販売価格オプション(消費税別)
Single UserUSD4,950 ⇒換算¥534,600見積依頼/購入/質問フォーム
Multi UserUSD5,950 ⇒換算¥642,600見積依頼/購入/質問フォーム
Global/corporate LicenseUSD7,950 ⇒換算¥858,600見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
本調査レポートでは、医薬品安全性監視(ファーマコビジランス)の世界市場について調査・分析し、医薬品安全性監視(ファーマコビジランス)の世界市場動向、医薬品安全性監視(ファーマコビジランス)の世界市場規模、市場予測、セグメント別医薬品安全性監視(ファーマコビジランス)市場分析、主要地域別市場規模、競争状況、関連企業情報などを含め、以下の構成でお届け致します。
【レポートの概要】

The global pharmacovigilance market size is expected to reach USD 11.64 billion by 2026, according to a new report by Grand View Research, Inc. It is projected to expand at a CAGR of 13.3% during the forecast period. Increasing incidence of Adverse Drug Reactions (ADR) is the key growth driver. The U.S. Food and Drug Administration (FDA) received approximately 253,017 serious adverse events and 44,693 deaths associated with ADRs in 2015. This shows the potential demand for implementing safety and Pharmacovigilance (PV) services.
According to the World Health Organization’s (WHO) report on pharmaceuticals consumption, medicines to treat chronic diseases accounted for a larger proportion of the total volume of drug consumption in non-hospital set ups. Owing to this, there has been a significant rise in the number of medicines made available to healthcare consumers. Rising demand for drugs has significantly heightened the need for the development of novel therapeutics via extensive clinical trials, which is expected to serve this market with lucrative opportunities.

Major pharmaceutical companies are involved in extensive R&D initiatives for development of innovative therapeutic molecules. This has resulted in increased drug development activities. Manufacturers are now focusing on remodeling their product development processes in an attempt to cater to patient needs across the globe. These factors are anticipated to fuel the demand for pharmacovigilance services during the forecast period.

Moreover, leading pharma companies in developed countries are focusing on outsourcing PV service in an attempt to reduce cost and to minimize operational expenses. This is anticipated to serve as an opportunity for contact research organizations in developing regions to gain more revenue share.

The companies operating in the pharmacovigilance market are undertaking strategic initiatives such as collaborations with the PV service providers to gain access to medical information and to manage PV workflows. For instance, In April 2017, Accenture entered in a collaborative agreement with BioCelebrate to develop a platform for aggregating and analyzing clinical information for improved drug developing efficiency, thus enhancing its R&D capabilities. These factors are anticipated to fuel the market growth.

Further key findings from the study suggest:

• Phase IV held a dominant market share owing to the extensive post marketing surveillance of pharmaceuticals and increasing number of ADR incidences in the market

• Phase III is anticipated to witness lucrative CAGR owing to increasing focus of pharmaceutical manufacturers on therapeutic development and safety monitoring

• In service provider segment, contract outsourcing held a significant market share, owing to shift in focus of pharmaceutical companies to outsourcing services to reduce operational cost

• Based on type of service, spontaneous reporting held the largest market share owing to its wide application in pharmacovigilance and benefits such as easy simulation of data sets for better drug comparison

• Research organizations segment is anticipated to exhibit lucrative CAGR over the forecast period owing to increasing R&D for the development of novel biologics and medical devices

• Asia Pacific pharmacovigilance market is anticipated to showcase lucrative CAGR in the forthcoming years

• Industry participants are focusing on increasing R&D activities to develop better pharmacovigilance services.

【レポートの目次】

Table of Contents

Chapter 1 Research Methodology & Scope
1.1 Market Segmentation & Scope
1.1.1 Estimates and Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased database:
1.3.2 GVR’s Internal Database
1.3.3 Secondary sources
1.3.4 Primary Research:
1.3.5 Details of Primary Research
1.3.5.1 Data for primary interviews in North america
1.3.5.2 Data for primary interviews in Europe
1.3.5.3 Data for primary interviews in Asia Pacific
1.3.5.4 Data for primary interviews in Middle East and Africa
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.6.1.1 Approach 1: Commodity Flow Approach
1.7 List of Secondary Sources
1.8 List of Primary Sources
1.9 Report Objectives
Chapter 2 Executive Summary
2.1 Market Outlook
2.1.1 Pharmacovigilance market Outlook, 2014 – 2026 (USD Million)
2.2 Segment Outlook
2.3 Competitive Outlook
2.4 Pharmacovigilance Market Summary, 2018
Chapter 3 Pharmacovigilance Market Variables, Trends & Scope
3.1 Market Lineage Outlook
3.1.1 Parent market analysis
3.1.2 Ancillary market Analysis
3.2 Penetration & Growth Prospect Mapping
3.3 Technology Timeline Overview
3.3.1 Technology Timeline Pharmacovigilance changing technology & adoption
3.4 Regulatory Framework
3.4.1 List of regulatory bodies
3.5 Pharmacovigilance Market Dynamics
3.5.1 Market driver analysis
3.5.1.1 Growing drug consumption and drug development rates
3.5.1.2 Increasing incidence of ADR and drug toxicity
3.5.1.3 Increasing trend of outsourcing pharmacovigilance services
3.5.2 Market restraint analysis
3.5.2.1 Lack of skilled labor
3.6 Pharmacovigilance Market Analysis Tools: Porters
3.6.1 Supplier Power
3.6.2 Buyer Power
3.6.3 Threat Of Substitutes
3.6.4 Threat Of New Entrants
3.6.5 Competitive Rivalary
3.7 PESTEL Analysis
3.7.1 Political Landscape
3.7.2 economic Landscape
3.7.3 technology Landscape
3.7.4 technology Landscape
3.7.5 social Landscape
3.8 Major Deals & Strategic Alliances Analysis
3.8.1 Mergers & Acquisitions
3.8.2 product launch
3.8.3 Expansion
3.8.4 Partnership & Collaborations
3.8.5 Market Entry Strategies
Chapter 4 Pharmacovigilance Market: Competitive Analysis
4.1 Market Participation Categorization
4.2 Public Companies
4.2.1 Company market position analysis
4.2.2 Competitive Dashboard Analysis
4.2.2.1 Market Differentiators
4.2.3 Company Market Share
4.2.4 Competitive Dashboard Analysis
4.3 Private Companies
4.3.1 List of key emerging companies
Chapter 5 Pharmacovigilance Market: Product Estimates & Trend Analysis
5.1 Product Market Share Analysis, 2018 & 2026
5.2 Product Dashboard
5.2.1 Preclinical
5.2.1.1 Preclinical market estimates and forecasts, 2014 – 2026 (USD Million)
5.2.2 Phase I
5.2.2.1 Phase I market estimates and forecasts, 2014 – 2026 (USD Million)
5.2.3 Phase II
5.2.3.1 Phase II market estimates and forecasts, 2014 – 2026 (USD Million)
5.2.4 Phase III
5.2.4.1 Phase III market estimates and forecasts, 2014 – 2026 (USD Million)
5.2.5 Phase IV
5.2.5.1 Phase IV market estimates and forecasts, 2014 – 2026 (USD Million)
Chapter 6 Pharmacovigilance Market: Service provider Estimates & Trend Analysis
6.1 Service provider Market Share Analysis, 2018 & 2026
6.2 Service Provider Dashboard
6.3 In house
6.3.1 In house market estimates and forecasts, 2014 – 2026 (USD Million)
6.4 Contract outsourcing
6.4.1 Contract outsourcing market estimates and forecasts, 2014 – 2026 (USD Million)
Chapter 7 Pharmacovigilance Market: Type Estimates & Trend Analysis
7.1 Type Market Share Analysis, 2018 & 2026
7.2 Type Dashboard
7.3 Spontaneous Reporting
7.3.1 Spontaneous Reporting market estimates and forecasts, 2014 – 2026 (USD Million)
7.4 Intensified ADR Reporting
7.4.1 Intensified ADR Reporting market estimates and forecasts, 2014 – 2026 (USD Million)
7.5 Targeted spontaneous reporting
7.5.1 Targeted spontaneous reporting market estimates and forecasts, 2014 – 2026 (USD Million)
7.6 Cohort Event Monitoring (CEM)
7.6.1 Cohort Event Monitoring (CEM) market estimates and forecasts, 2014 – 2026 (USD Million)
7.7 EHR Mining
7.7.1 EHR Mining market estimates and forecasts, 2014 – 2026 (USD Million)
Chapter 8 Pharmacovigilance Market: End Use Estimates & Trend Analysis
8.1 End Use Market Share Analysis, 2018 & 2026
8.2 End Use Dashboard
8.3 Hospitals
8.3.1 Hospitals market estimates and forecasts, 2014 – 2026 (USD Million)
8.4 Research organizations
8.4.1 Research organizations market estimates and forecasts, 2014 – 2026 (USD Million)
8.5 Industrial
8.5.1 Industrial market estimates and forecasts, 2014 – 2026 (USD Million)
Chapter 9 Pharmacovigilance Market: Regional Estimates & Trend Analysis, By, Product, Service Providers, Type, And End Use
9.1 Regional Market Snapshot
9.2 Market Share Analysis by Country, 2018
9.2.1 North America
9.2.2 Europe
9.2.3 Asia Pacific
9.2.4 Latin America
9.2.5 MEA
9.3 North America
9.3.1 North America Pharmacovigilance market estimates and forecasts, 2014 – 2026 (USD Million)
9.3.2 U.S.
9.3.2.1 U.S. Pharmacovigilance market estimates and forecasts, 2014 – 2026 (USD Million)
9.3.3 Canada
9.3.3.1 Canada Pharmacovigilance market estimates and forecasts, 2014 – 2026 (USD Million)
9.4 Europe
9.4.1 Europe Pharmacovigilance MARKET estimates and forecasts, 2014 – 2026 (USD Million)
9.4.2 U.K.
9.4.2.1 U.K. Pharmacovigilance market estimates and forecasts, 2014 – 2026 (USD Million)
9.4.3 Germany
9.4.3.1 Germany Pharmacovigilance market estimates and forecasts, 2014 – 2026 (USD Million)
9.4.4 France
9.4.4.1 France Pharmacovigilance market estimates and forecasts, 2014 – 2026 (USD Million)
9.4.5 Italy
9.4.5.1 Italy Pharmacovigilance market estimates and forecasts, 2014 – 2026 (USD Million)
9.4.6 Russia
9.4.6.1 Russia Pharmacovigilance market estimates and forecasts, 2014 – 2026 (USD Million)
9.5 Asia Pacific
9.5.1 Asia Pacific Pharmacovigilance market estimates and forecasts, 2014 – 2026 (USD Million)
9.5.2 Japan
9.5.2.1 Japan Pharmacovigilance market estimates and forecasts, 2014 – 2026 (USD Million)
9.5.3 China
9.5.3.1 China Pharmacovigilance market estimates and forecasts, 2014 – 2026 (USD Million)
9.5.4 India
9.5.4.1 India Pharmacovigilance market estimates and forecasts, 2014 – 2026 (USD Million)
9.6 Latin America
9.6.1 Latin America Pharmacovigilance market estimates and forecasts, 2014 – 2026 (USD Million)
9.6.2 Mexico
9.6.2.1 Mexico Pharmacovigilance market estimates and forecasts, 2014 – 2026 (USD Million)
9.6.3 Brazil
9.6.3.1 Brazil Pharmacovigilance market estimates and forecasts, 2014 – 2026 (USD Million)
9.7 MEA
9.7.1 MEA Pharmacovigilance market estimates and forecasts, 2014 – 2026 (USD Million)
9.7.2 South Africa
9.7.2.1 South Africa Pharmacovigilance market estimates and forecasts, 2014 – 2026 (USD Million)
9.7.3 Saudi Arabia
9.7.3.1 Saudi Arabia Pharmacovigilance market estimates and forecasts, 2014 – 2026 (USD Million)
Chapter 10 Company Profiles
10.1 Accenture
10.1.1 Company overview
10.1.2 Financial performance
10.1.3 Product benchmarking
10.1.4 Strategic initiatives
10.2 Clinquest Group B.V.
10.2.1 Company overview
10.2.2 Product benchmarking
10.2.3 Strategic initiatives
10.3 Cognizant
10.3.1 Company overview
10.3.2 Financial Performance
10.3.3 Product benchmarking
10.3.4 Strategic initiatives
10.4 Laboratory Corporation of America Holdings
10.4.1 Company overview
10.4.2 Financial Performance
10.4.3 Product benchmarking
10.4.4 Strategic initiatives
10.5 IBM Corporation
10.5.1 Company overview
10.5.2 Product benchmarking
10.5.3 Strategic initiatives
10.6 ArisGlobal
10.6.1 Company overview
10.6.2 Financial Performance
10.6.3 Product benchmarking
10.6.4 Strategic initiatives
10.7 ICON Plc
10.7.1 Company overview
10.7.2 Product benchmarking
10.8 Capgemini
10.8.1 Company overview
10.8.2 Financial Performance
10.8.3 Product benchmarking
10.8.4 Strategic initiatives
10.9 iMEDGlobal
10.9.1 Company overview
10.9.2 Financial performance
10.9.3 Product benchmarking
10.9.4 Strategic initiatives
10.10 ITClinical
10.10.1 Company overview
10.10.2 Financial performance
10.10.3 Product benchmarking
10.10.4 Strategic initiatives
10.11 Foresight Group International AG
10.11.1 Company overview
10.11.2 Financial performance
10.11.3 Product benchmarking
10.11.4 Strategic initiatives
10.12 TAKE Solutions
10.12.1 Company overview
10.12.2 Financial performance
10.12.3 Product benchmarking
10.12.4 Strategic initiatives
10.13 PAREXEL International Corporation
10.13.1 Company overview
10.13.2 Financial performance
10.13.3 Product benchmarking
10.13.4 Strategic initiatives
10.14 BioClinica, Inc.
10.14.1 Company overview
10.14.2 Financial performance
10.14.3 Product benchmarking
10.14.4 Strategic initiatives
10.15 Wipro Limited
10.15.1 Company overview
10.15.2 Financial performance
10.15.3 Product benchmarking
10.15.4 Strategic initiatives
10.16 UNITED BIOSOURCE CORPORATION
10.16.1 Company overview
10.16.2 Financial performance
10.16.3 Product benchmarking
10.16.4 Strategic initiatives

List of Tables

TABLE 1 List of secondary sources
TABLE 2 List of key emerging companies
TABLE 3 North America Pharmacovigilance market estimates and forecasts, by product, 2014 - 2025 (USD Million)
TABLE 4 North America Pharmacovigilance market estimates and forecasts, by service provider, 2014 - 2025 (USD Million)
TABLE 5 North America Pharmacovigilance market estimates and forecasts, by type, 2014 - 2025 (USD Million)
TABLE 6 North America Pharmacovigilance market estimates and forecasts, by end use, 2014 - 2025 (USD Million)
TABLE 7 U.S. Pharmacovigilance market estimates and forecasts, by product, 2014 - 2025 (USD Million)
TABLE 8 U.S. Pharmacovigilance market estimates and forecasts, by service provider, 2014 - 2025 (USD Million)
TABLE 9 U.S. Pharmacovigilance market estimates and forecasts, by type, 2014 - 2025 (USD Million)
TABLE 10 U.S. Pharmacovigilance market estimates and forecasts, by end use, 2014 - 2025 (USD Million)
TABLE 11 Canada Pharmacovigilance market estimates and forecasts, by product, 2014 - 2025 (USD Million)
TABLE 12 Canada Pharmacovigilance market estimates and forecasts, by service provider, 2014 - 2025 (USD Million)
TABLE 13 Canada Pharmacovigilance market estimates and forecasts, by type, 2014 - 2025 (USD Million)
TABLE 14 Canada Pharmacovigilance market estimates and forecasts, by end use, 2014 - 2025 (USD Million)
TABLE 15 Europe Pharmacovigilance market estimates and forecasts, by product, 2014 - 2025 (USD Million)
TABLE 16 Europe Pharmacovigilance market estimates and forecasts, by service provider, 2014 - 2025 (USD Million)
TABLE 17 Europe Pharmacovigilance market estimates and forecasts, by type, 2014 - 2025 (USD Million)
TABLE 18 Europe Pharmacovigilance market estimates and forecasts, by end use, 2014 - 2025 (USD Million)
TABLE 19 U.K. Pharmacovigilance market estimates and forecasts, by product, 2014 - 2025 (USD Million)
TABLE 20 U.K. Pharmacovigilance market estimates and forecasts, by service provider, 2014 - 2025 (USD Million)
TABLE 21 U.K. Pharmacovigilance market estimates and forecasts, by type, 2014 - 2025 (USD Million)
TABLE 22 U.K. Pharmacovigilance market estimates and forecasts, by end use, 2014 - 2025 (USD Million)
TABLE 23 Germany Pharmacovigilance market estimates and forecasts, by product, 2014 - 2025 (USD Million)
TABLE 24 Germany Pharmacovigilance market estimates and forecasts, by type, 2014 - 2025 (USD Million)
TABLE 25 Germany Pharmacovigilance market estimates and forecasts, by end use, 2014 - 2025 (USD Million)
TABLE 26 France Pharmacovigilance market estimates and forecasts, by product, 2014 - 2025 (USD Million)
TABLE 27 France Pharmacovigilance market estimates and forecasts, by service provider, 2014 - 2025 (USD Million)
TABLE 28 France Pharmacovigilance market estimates and forecasts, by type, 2014 - 2025 (USD Million)
TABLE 29 France Pharmacovigilance market estimates and forecasts, by end use, 2014 - 2025 (USD Million)
TABLE 30 Italy Pharmacovigilance market estimates and forecasts, by product, 2014 - 2025 (USD Million)
TABLE 31 Italy Pharmacovigilance market estimates and forecasts, by service provider, 2014 - 2025 (USD Million)
TABLE 32 Italy Pharmacovigilance market estimates and forecasts, by type, 2014 - 2025 (USD Million)
TABLE 33 Italy Pharmacovigilance market estimates and forecasts, by end use, 2014 - 2025 (USD Million)
TABLE 34 Russia Pharmacovigilance market estimates and forecasts, by product, 2014 - 2025 (USD Million)
TABLE 35 Russia Pharmacovigilance market estimates and forecasts, by service provider, 2014 - 2025 (USD Million)
TABLE 36 Russia Pharmacovigilance market estimates and forecasts, by type, 2014 - 2025 (USD Million)
TABLE 37 Russia Pharmacovigilance market estimates and forecasts, by end use, 2014 - 2025 (USD Million)
TABLE 38 Asia Pacific Pharmacovigilance market estimates and forecasts, by product, 2014 - 2025 (USD Million)
TABLE 39 Asia Pacific Pharmacovigilance market estimates and forecasts, by service provider, 2014 - 2025 (USD Million)
TABLE 40 Asia Pacific Pharmacovigilance market estimates and forecasts, by type, 2014 - 2025 (USD Million)
TABLE 41 Asia Pacific Pharmacovigilance market estimates and forecasts, by end use, 2014 - 2025 (USD Million)
TABLE 42 Japan Pharmacovigilance market estimates and forecasts, by product, 2014 - 2025 (USD Million)
TABLE 43 Japan Pharmacovigilance market estimates and forecasts, by service provider, 2014 - 2025 (USD Million)
TABLE 44 Japan Pharmacovigilance market estimates and forecasts, by type, 2014 - 2025 (USD Million)
TABLE 45 Japan Pharmacovigilance market estimates and forecasts, by end use, 2014 - 2025 (USD Million)
TABLE 46 China Pharmacovigilance market estimates and forecasts, by product, 2014 - 2025 (USD Million)
TABLE 47 China Pharmacovigilance market estimates and forecasts, by service provider, 2014 - 2025 (USD Million)
TABLE 48 China Pharmacovigilance market estimates and forecasts, by type, 2014 - 2025 (USD Million)
TABLE 49 China Pharmacovigilance market estimates and forecasts, by end use, 2014 - 2025 (USD Million)
TABLE 50 India Pharmacovigilance market estimates and forecasts, by product, 2014 - 2025 (USD Million)
TABLE 51 India Pharmacovigilance market estimates and forecasts, by service provider, 2014 - 2025 (USD Million)
TABLE 52 India Pharmacovigilance market estimates and forecasts, by type, 2014 - 2025 (USD Million)
TABLE 53 India Pharmacovigilance market estimates and forecasts, by end use, 2014 - 2025 (USD Million)
TABLE 54 Latin America Pharmacovigilance market estimates and forecasts, by product, 2014 - 2025 (USD Million)
TABLE 55 Latin America Pharmacovigilance market estimates and forecasts, by service provider, 2014 - 2025 (USD Million)
TABLE 56 Latin America Pharmacovigilance market estimates and forecasts, by type, 2014 - 2025 (USD Million)
TABLE 57 Latin America Pharmacovigilance market estimates and forecasts, by end use, 2014 - 2025 (USD Million)
TABLE 58 Brazil Pharmacovigilance market estimates and forecasts, by product, 2014 - 2025 (USD Million)
TABLE 59 Brazil Pharmacovigilance market estimates and forecasts, by service provider, 2014 - 2025 (USD Million)
TABLE 60 Brazil Pharmacovigilance market estimates and forecasts, by type, 2014 - 2025 (USD Million)
TABLE 61 Brazil Pharmacovigilance market estimates and forecasts, by end use, 2014 - 2025 (USD Million)
TABLE 62 Mexico Pharmacovigilance market estimates and forecasts, by product, 2014 - 2025 (USD Million)
TABLE 63 Mexico Pharmacovigilance market estimates and forecasts, by service provider, 2014 - 2025 (USD Million)
TABLE 64 Mexico Pharmacovigilance market estimates and forecasts, by type, 2014 - 2025 (USD Million)
TABLE 65 Mexico Pharmacovigilance market estimates and forecasts, by end use, 2014 - 2025 (USD Million)
TABLE 66 MEA Pharmacovigilance market estimates and forecasts, by product, 2014 - 2025 (USD Million)
TABLE 67 MEA Pharmacovigilance market estimates and forecasts, by service provider, 2014 - 2025 (USD Million)
TABLE 68 MEA Pharmacovigilance market estimates and forecasts, by type, 2014 - 2025 (USD Million)
TABLE 69 MEA Pharmacovigilance market estimates and forecasts, by end use, 2014 - 2025 (USD Million)
TABLE 70 South Africa Pharmacovigilance market estimates and forecasts, by product, 2014 - 2025 (USD Million)
TABLE 71 South Africa Pharmacovigilance market estimates and forecasts, by service provider, 2014 - 2025 (USD Million)
TABLE 72 South Africa Pharmacovigilance market estimates and forecasts, by type, 2014 - 2025 (USD Million)
TABLE 73 South Africa Pharmacovigilance market estimates and forecasts, by end use, 2014 - 2025 (USD Million)
TABLE 74 Saudi Arabia Pharmacovigilance market estimates and forecasts, by product, 2014 - 2025 (USD Million)
TABLE 75 Saudi Arabia Pharmacovigilance market estimates and forecasts, by service provider, 2014 - 2025 (USD Million)
TABLE 76 Saudi Arabia Pharmacovigilance market estimates and forecasts, by type, 2014 - 2025 (USD Million)
TABLE 77 Saudi Arabia Pharmacovigilance market estimates and forecasts, by end use, 2014 - 2025 (USD Million)

【掲載企業】

Accenture, Clinquest Group B.V., Cognizant, Laboratory Corporation of America Holdings, IBM Corporation, ArisGlobal, ICON Plc, Capgemini, iMEDGlobal, ITClinical, Foresight Group International AG, TAKE Solutions, PAREXEL International Corporation, BioClinica, Inc., Wipro Limited, UNITED BIOSOURCE CORPORATION

★調査レポート[医薬品安全性監視(ファーマコビジランス)の世界市場:臨床試験段階別(前臨床、第Ⅰ相、第Ⅱ相、第Ⅲ相、第Ⅳ相)、サービスプロバイダー別(インハウス、契約アウトソーシング)、種類別、エンドユーズ別] (コード:GV905091)販売に関する免責事項を必ずご確認ください。
★調査レポート[医薬品安全性監視(ファーマコビジランス)の世界市場:臨床試験段階別(前臨床、第Ⅰ相、第Ⅱ相、第Ⅲ相、第Ⅳ相)、サービスプロバイダー別(インハウス、契約アウトソーシング)、種類別、エンドユーズ別]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆